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Abstract: Do community pharmacists coming from different educational backgrounds 
rank the importance of competences for practice differently—or is the way in which they 
see their profession more influenced by practice than university education? A survey was 
carried out on 68 competences for pharmacy practice in seven countries with different 
pharmacy education systems in terms of the relative importance of the subject areas 
chemical and medicinal sciences. Community pharmacists were asked to rank the 
competences in terms of relative importance for practice; competences were divided into 
personal and patient-care competences. The ranking was very similar in the seven 
countries suggesting that evaluation of competences for practice is based more on 
professional experience than on prior university education. There were some differences 
for instance in research-related competences and these may be influenced, by education. 
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1. Introduction 
In 1985, the then European Economic Community (EEC) published a directive [1] on pharmacy 
practice that assumed that pharmacy education in the EEC was broadly comparable and, thus, that the 
European education system was producing pharmacists with similar competences. In the early 1990s, 
the European Association of Faculties of Pharmacy (EAFP) [2] questioned these assumptions [3]. 
EAFP surveyed pharmacy courses in the 11 EEC members and found that although the emphasis in 
most faculties was on chemical sciences, there was great variability in pharmacy degree courses in the 
EEC regarding the percentages of time spent on different subjects [4]. 
At that time it was hoped that European integration would produce greater harmonization in 
pharmacy education and therefore in competences for practice. In 2011, the PHARMINE 
(“PHARMacy Education IN Europe”) project [5] revisited this problem. In the 20-year interval 
between the two studies there was a shift in several countries from chemical to medicinal sciences, 
albeit, overall variability in degree courses from country to country had not decreased [6]. PHARMINE 
reflected upon whether differences in pharmacy degrees could be minored by expressing content as 
competences rather than subjects. 
As a follow-up to PHARMINE, a second study, the PHAR-QA (“Quality Assurance in European 
PHARmacy-Education and Training”) project [7], again funded by the European Commission, asked 
community pharmacists to rank competences for pharmacy practice. 
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This paper combines the results of the PHARMINE and PHAR-QA studies. It looks at whether the 
nature of the degree course (in terms of the relative importance of the subject areas chemical and 
medicinal sciences taken as an indication of a more “scientific” or a more “clinical” course) has any 
influence on the way in which community pharmacists ranked the competences they consider are 
required for practice. The paper evaluates to what extent university education or professional experience 
can influence the way in which practicing community pharmacists judge their métier and how the 
balance between these two factors could be altered by the introduction of competence-based education. 
2. Experimental Section 
In the PHARMINE project, country profiles for pharmacy education and training were drawn up 
with the help of academics, students, professional pharmacists, and their organizations, as well as 
representatives of different governmental bodies concerned with pharmacy in the 47 countries of the 
European Higher Education Area [8]. Amongst others, one of the areas explored in the country profiles 
was the structure of the pharmacy degree course that was divided into six subject areas: chemical 
sciences, medicinal sciences, biological sciences, pharmaceutical technology, and law and societal 
issues. A subject area course index was calculated as: ((percentage of contact hours spent on medicinal 
subjects/percentage of contact hours spent on chemical subjects) x 100) using data from the PHARMINE 
study, as given in the 2014 paper on heterogeneity of pharmacy education cited above [6]. 
In the PHARMINE study, “medicinal subjects” included contact hours in the subjects of anatomy, 
physiology, medical terminology, pathology, histology, nutrition, pharmacology/pharmacotherapy, 
toxicology, hematology, immunology, parasitology, hygiene, emergency therapy, non-pharmacological 
treatment, clinical chemistry/bio-analysis, radiochemistry, dispensing process, drug prescription, 
prescription analysis (detection of adverse effects and drug interactions), generic drugs, planning, 
running and interpretation of the data, of clinical trials, medical devices, orthopedics, over the counter 
medicines, complementary therapy, at-home support and care, skin illness and treatment, homeopathy, 
phyto-therapy, drugs in veterinary medicine, pharmaceutical care, pharmaceutical therapy of illness, 
and disease. “Chemical subjects” included contact hours in the subjects of general and inorganic 
chemistry, medical physico-chemistry, organic chemistry, pharmacopeia analysis, analytical 
chemistry, and pharmaceutical chemistry including analysis of medicinal products. 
Ranking data on competences for practice were taken from the PHAR-QA surveymonkey [9] 
questionnaire that was available online from 14 January 2014 to 1 November 2014 i.e., 8.5 months. 
Contacts were made by electronic and other means with the same groups as in the PHARMINE study 
(see previously). Post hoc analysis of the data allowed the creation of six subgroups: academics, 
students, community pharmacists, hospital pharmacists, industrial pharmacists, and pharmacists 
working in other areas. Here we will present the data for community pharmacists; data for other 
professional categories will be presented elsewhere [10]. 
The first six questions of the PHAR-QA survey were on the profile of the respondent asking, 
amongst others, country of residence, current occupation, and duration of activity. 
Questions seven through 19 asked about 13 groups of competences with a total of 68 competences  
(see annex). Questions in groups seven through 11 were concerned with personal competences and in 
groups 12 through 19 with patient care competences. 
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Respondents were asked to rank the proposals for competences with a Likert scale: 
1. Not important = Can be ignored. 
2. Quite important = Valuable but not obligatory. 
3. Very important = Obligatory with exceptions depending upon field of pharmacy practice. 
4. Essential = Obligatory. 
Results are presented in the form of “scores” based on the methodology used in MEDINE2 [11]:  
score = (frequency rank 3 + frequency rank 4) as % of total frequency. Scores give more granularity 
and a better pictorial representation than the basic Likert data. Data were obtained from 39 European 
countries. Data presented here are from the seven European Union member states in which the number 
of respondents was > 10 (Table 1). Analysis was limited to the European Union as its 28 member 
states come under the directive on sectoral professions such as pharmacy [12]. One of the annexes of 
this directive lists the subject areas that are to be taught in the pharmacy degree course in the European 
Union. Of the 28 member states only seven provided 10 or more community pharmacists respondents. 
Statistical Analysis 
Results are also expressed as medians with 25 and 75% percentiles; differences among countries 
were analyzed using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. All 
statistics were performed using GraphPad software [13]. 
3. Results and Discussion 
In Table 1 are the medians for duration of practice. Kruskal-Wallace analysis showed a significant 
effect of country (P = 0.0014) and the Dunn’s multiple comparisons test showed that the duration of 
practice of the respondents from the Czech Republic was lower than that of respondents from 
Germany, Ireland or Spain. None of the other comparisons were significant. 
Table 1 also shows the medicinal sciences/chemical sciences scores. In Germany the degree course 
is more “chemical”; in Belgium, the Czech Republic, and Spain the importance of the two subject 
areas is equal; in The Netherlands and the United Kingdom there is a more “medicinal” course, and 
this is even more pronounced in Ireland. The medicinal/chemical ratio varies almost four-fold from 
Germany (0.7) to Ireland (2.6). 
Finally, Table 1 shows overall the median rankings for competences (n = 68). The Kruskal-Wallis 
test showed a significant difference amongst countries (P = 0.0006) with a significantly higher median 
for Spain compared to Belgium, Germany, and Ireland. None of the other multiple comparisons 
amongst countries reached statistical significance. 
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Table 1. Characteristics of the seven countries, the medicinal sciences/chemical sciences indices (latter data from the PHARMINE study), and 
the rankings for competences. 
Country Number of respondents 
Duration of activity 
(years; median, 25% and 
75% percentiles) 
Medicinal sciences % Chemical sciences % Medicinal/chemical score 
Ranking of competences 
(median, 25% and 75% 
percentiles, n = 68) 
Belgium 25 10/5/20 24 27 1.1 81/63/91 
Czech Republic 15 5/5/15 19 17 1.1 84/67/92 
Germany 13 30/15/30 28 40 0.7 82/67/92 
Ireland 13 20/10/33 36 14 2.6 77/55/92 
Spain 27 15/10/30 28 24 1.2 91/82/96 
The Netherlands 18 20/5/23 31 20 1.6 82/57/94 
United  
Kingdom 
48 10/5/20 24 14 1.7 87/59/96 
Pharmacy 2015, 3  142 
 
Figure 1 shows the ranking by the seven countries of the 68 competences. This is presented as a 
radar chart. Radar charts are a useful way to display multivariate observations with an arbitrary 
number of variables. It allows one to find clusters and also to identify outliers [14]. This radar chart 
presentation allows an easy overview of the global rankings of competences. It underlines the fact that 
overall the global rankings by the different countries are similar, with similar highs and lows. This is 
especially true for the left-hand side of the Figure that represents the rankings for the patient care 
competences (number 43 through 68). Opinions of the relative importance of such competences appear 
to be formed by work experience rather than university education. In answer to the question “do 
community pharmacists coming from different educational backgrounds rank the importance of 
competences for practice differently” the answer would be no in the case of patient care competences. 
Examination of Figure 1 shows that the ranking of competences for practice is very similar in seven 
countries that have different systems of pharmacy education. It should be noted that the ranking score 
is based on a combination of ranks 3 and 4 that specify that competences are “obligatory”. 
 
Figure 1. Radar chart of the ranking scores (on the central vertical axe, 0%–100%) for the 
68 competences (on the circumference) by the seven countries (in different colours). 
Dotted lines separate the 13 competence groups (see annex) in Figure 1 are given the 
ranking scores for the 68 competences by the seven countries. 
There are more differences in the right-hand side of the Figure that represents personal 
competences. Competence 6 is an interesting case. The difference between minimum and maximum 
for country rankings in group 7 (“personal competences: learning and knowledge”) competence 6 
(“ability to design and conduct research using appropriate methodology”) was large (63, see Table 
A1); Spain, which has a “balanced” course with a medicinal sciences/chemical sciences index of 1.2, 
ranked highest with 80%. Ireland and the Netherlands which have more “medical” indices of 2.6 and 
1.6, respectively, showed the lowest rankings for competence 6: 18 and 17%, respectively. Spain 
also ranked highest for all competences. In the research-related group 11 (“personal competences: 
understanding of industrial pharmacy”) Spain scored highest for all 5 competences. Thus differences 
Pharmacy 2015, 3  143 
 
for Spain may be influenced by education rather than professional experience, albeit, Germany,  
which has a more “chemical” index (0.7), did not rank competence 6 or the competences in group 11 
particularly high. 
Several provisos should be added. It is possible that differences in ranking scores are related to 
duration of practice (i.e., numbers of years since leaving university) rather than to course content. With 
the median years of practice being significantly different it could very well be that older pharmacists in 
a given country took a very different course of study 30–40 years ago than younger pharmacists from 
the same country. Furthermore, it is likely the mix of medicinal/chemical subjects would have differed 
within countries for participants dependent on when they studied especially as there has been a move 
towards more medicinal sciences in the past 20 years (see introduction). This cannot be tested, 
however, as numbers in the different groups do not allow the creation of subgroups based on duration 
of practice. Some comments can be made on the basis of the existing data. The community pharmacist 
respondents from the Czech Republic were younger than in several other countries, but the Czech 
Republic community pharmacists did not show any marked differences with other countries as far as 
ranking of competences was concerned. Spanish community pharmacists did show a specific pattern of 
ranking in several groups of competences but their median duration of practice was mid-range. 
The conclusion of this paper relies on the fact that the curricula investigated are as different as 
possible in the relative importance of “medicinal” versus “chemical” sciences component. The seven 
countries selected were selected on the basis of providing more than 10 respondents. Nonetheless they 
do represent a significantly wide range of scores. Ireland has the highest value of the 26 European 
Union member states that have pharmacy departments (1st/26), and Germany the 3rd from the lowest 
(23rd/26)vi. 
The PHARMINE study cited above showed that a competence approach is rarely used in pre-graduate 
pharmacy education in Europe. There have been several studies on the use of a competence framework 
to monitor and improve pharmacy practice in a working environment. A study using the general level 
framework with Singaporean hospital pharmacists showed that all but eight of the 63 behavioral 
descriptors improved in nine months [15]. A similar study with hospital pharmacists in Queensland showed 
an improvement in 35 out of 61 competences [16]. Studies have also been conducted in Canada [17]. and 
elsewhere. The results of all these studies are that competence frameworks are useful tools to monitor and 
improve performance. 
4. Conclusions 
This study shows that community pharmacists largely form their opinions on the importance of 
competences of the basis of work experience rather than university education. The move to harmonize 
European pharmacy practice expressed in the 1980s seems to have been successful, as judged from the 
similar way in which community pharmacists from different countries rank competences for practice. 
However this is less the result of harmonization of pharmacy education that still shows wide diversity. 
The short-term perspective of this work is the modification of the existing questionnaire according 
to the results obtained and the endorsement of the modified version. 
The long-term perspective is the introduction of competence-based learning into the university 
curriculum for pharmacy. This is being discussed in Australia and New Zealand [18] and elsewhere. It 
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now needs to be considered in Europe. Our results suggest that differences in university pharmacy 
programs are not crucial in the development of specific competencies (at least in the field of 
community pharmacy, where the majority of pharmacists work). Thus, we do not need a very stringent 
and tight framework for curricula of pharmacy education. Academia provides graduates with 
competencies as “novices” (according to five-stage model of competencies proposed by Dreyfus and 
Dreyfus, 1980 [19]). Thus, competence-based learning in universities would provide a sound foundation 
allowing graduates to gather experience through practical training in the real job environment. 
Furthermore, academic freedom as to course content should be incorporated into quality assurance of 
pharmacy education especially when EU directive is “translated” into national frameworks. 
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Appendix 
Table A1. Ranking of competences by countries. 
Seq. Competence Belgium 
Czech 
Republic 
Germany Ireland Spain 
The 
Netherlands 
United 
Kingdom 
Min. Max. 
Range: 
max–min. 
 Group 7. Personal competences: learning and knowledge           
1 
1. Ability to identify learning needs and to learn 
independently (including continuous professional 
development (CPD)). 
83 100 85 85 85 94 96 83 100 17 
2 
2. Analysis: ability to apply logic to problem solving, 
evaluating pros and cons and following up on the 
solution found. 
83 93 92 92 93 94 92 83 94 11 
3 
3. Synthesis: capacity to gather and critically appraise 
relevant knowledge and to summarise the key points. 
83 93 77 77 93 89 90 77 93 16 
4 
4. Capacity to evaluate scientific data in line with current 
scientific and technological knowledge. 
78 67 77 77 92 78 79 67 92 25 
5 
5. Ability to interpret preclinical and clinical 
evidence-based medical science and apply the 
knowledge to pharmaceutical practice. 
63 73 62 69 92 83 79 62 92 31 
6 
6. Ability to design and conduct research using 
appropriate methodology. 
33 29 31 18 80 17 36 17 80 63 
7 
7. Ability to maintain current knowledge of relevant 
legislation and codes of pharmacy practice. 
88 100 75 92 89 89 93 75 100 25 
 Group 8. Personal competences: values           
8 
1. Demonstrate a professional approach to tasks and 
human relations. 
92 86 85 100 100 100 96 85 100 15 
9 2. Demonstrate the ability to maintain confidentiality. 100 86 85 100 96 100 100 85 100 15 
10 
3. Take full personal responsibility for patient care and 
other aspects of one’s practice. 
92 100 92 92 100 100 100 92 100 8 
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Table A1. Cont. 
Seq. Competence Belgium 
Czech 
Republic 
Germany Ireland Spain 
The 
Netherlands 
United 
Kingdom 
Min. Max. 
Range: 
max–min. 
11 
4. Inspire the confidence of others in one’s actions  
and advice. 
87 79 85 92 96 88 96 79 96 18 
12 5. Demonstrate high ethical standards. 92 93 85 92 100 100 98 85 100 15 
 
Group 9. Personal competences: communication and 
organisational skills. 
          
13 1. Effective communication skills (both orally and written). 87 100 92 92 96 100 100 87 100 13 
14 2. Effective use of information technology. 78 85 92 85 92 81 92 78 92 14 
15 3. Ability to work effectively as part of a team. 78 77 92 85 100 94 98 77 100 23 
16 
4. Ability to identify and implement legal and 
professional requirements relating to employment (e.g., 
for pharmacy technicians) and to safety in the workplace. 
65 75 77 85 92 88 81 65 92 27 
17 5. Ability to contribute to the learning and training of staff. 65 85 69 77 100 81 83 65 100 35 
18 
6. Ability to design and manage the development 
processes in the production of medicines. 
52 25 50 25 76 25 26 25 76 51 
19 
7. Ability to identify and manage risk and quality of 
service issues. 
82 85 69 75 92 94 83 69 94 25 
20 8. Ability to identify the need for new services. 62 67 62 54 85 56 59 54 85 31 
21 
9. Ability to communicate in English and/or locally 
relevant languages. 
52 46 46 100 77 63 100 46 100 54 
22 10. Ability to evaluate issues related to quality of service. 68 46 69 75 92 75 90 46 92 46 
23 
11. Ability to negotiate, understand a business 
environment and develop entrepreneurship.  
61 58 67 50 81 69 43 43 81 37 
 
Group 10. Personal competences: knowledge of different 
areas of the science of medicines. 
          
24 1. Plant and animal biology. 52 62 67 31 54 27 35 27 67 40 
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Table A1. Cont. 
Seq. Competence Belgium 
Czech 
Republic 
Germany Ireland Spain 
The 
Netherlands 
United 
Kingdom 
Min. Max. 
Range: 
max–min. 
25 2. Physics. 26 31 25 8 27 60 13 8 60 52 
26 3. General and inorganic chemistry. 57 46 42 31 46 50 39 31 57 26 
27 4. Organic and medicinal/pharmaceutical chemistry. 83 77 75 69 69 63 53 53 83 29 
28 5. Analytical chemistry. 57 46 67 31 58 38 33 31 67 36 
29 
6. General and applied biochemistry (medicinal  
and clinical). 
74 77 83 46 85 56 62 46 85 38 
30 7. Anatomy and physiology; medical terminology. 96 92 92 77 96 88 88 77 96 19 
31 8. Microbiology.  65 62 83 54 92 69 78 54 92 38 
32 9. Pharmacology including pharmacokinetics. 96 100 92 100 92 94 91 91 100 9 
33 10. Pharmacotherapy and pharmaco-epidemiology. 96 100 92 92 92 100 85 85 100 15 
34 
11. Pharmaceutical technology including analyses of 
medicinal products. 
61 77 75 58 69 44 50 44 77 33 
35 12. Toxicology.  96 62 67 75 69 81 62 62 96 34 
36 13. Pharmacognosy. 83 85 50 46 85 50 46 46 85 39 
37 14. Legislation and professional ethics. 91 92 67 92 85 88 96 67 96 29 
 
Group 11. Personal competences: understanding of 
industrial pharmacy. 
          
38 
1. Current knowledge of design, synthesis, isolation, 
characterisation and biological evaluation of  
active substances. 
58 42 36 25 75 7 28 7 75 68 
39 
2. Current knowledge of good manufacturing practice 
(GMP) and of good laboratory practice (GLP). 
63 50 64 25 83 43 42 25 83 58 
40 
3. Current knowledge of European directives on qualified 
persons (QPs). 
47 40 55 25 61 20 27 20 61 41 
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Table A1. Cont. 
Seq. Competence Belgium 
Czech 
Republic 
Germany Ireland Spain 
The 
Netherlands 
United 
Kingdom 
Min. Max. 
Range: 
max–min. 
41 
4. Current knowledge of drug registration, licensing 
and marketing. 
42 67 45 33 79 27 57 27 79 53 
42 5. Current knowledge of good clinical practice (GCP). 74 67 55 63 79 40 71 40 79 39 
 
Group 12. Patient care competences: patient consultation 
and assessment. 
          
43 1. Ability to perform and interpret medical laboratory tests. 73 77 83 67 92 67 56 56 92 36 
44 
2. Ability to perform appropriate diagnostic or 
physiological tests to inform clinical decision making 
e.g., measurement of blood pressure. 
48 85 83 77 88 47 69 47 88 41 
45 
3. Ability to recognise when referral to another member 
of the healthcare team is needed because a potential 
clinical problem is identified (pharmaceutical, medical, 
psychological or social). 
91 85 92 92 92 87 98 85 98 13 
 
Group 13. Patient care competences: need for  
drug treatment. 
          
46 
1. Retrieval and interpretation of relevant information on 
the patient's clinical background. 
91 92 92 69 88 93 87 69 93 24 
47 
2. Retrieval and interpretation of an accurate and 
comprehensive drug history if and when required. 
100 100 92 85 96 93 91 85 100 15 
48 
3. Identification of non-adherence and implementation of 
appropriate patient intervention. 
86 100 91 77 92 93 96 77 100 23 
49 
4. Ability to advise to physicians and—in some cases—
prescribe medication. 
81 100 91 85 96 100 96 81 100 19 
 Group 14. Patient care competences: drug interactions.           
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Table A1. Cont. 
Seq. Competence Belgium 
Czech 
Republic 
Germany Ireland Spain 
The 
Netherlands 
United 
Kingdom 
Min. Max. 
Range: 
max–min. 
50 
1. Identification, understanding and prioritisation of 
drug-drug interactions at a molecular level (e.g., use of 
codeine with paracetamol). 
95 100 92 100 100 93 87 87 100 13 
51 
2. Identification, understanding, and prioritisation of drug-
patient interactions, including those that preclude or require 
the use of a specific drug (e.g., trastuzumab for treatment of 
breast cancer in women with HER2 overexpression).  
91 92 83 92 100 100 93 83 100 17 
52 
3. Identification, understanding, and prioritisation of 
drug-disease interactions (e.g., NSAIDs in heart failure). 
100 100 92 100 100 100 96 92 100 8 
 
Group 15. Patient care competences: provision of  
drug product. 
          
53 
1. Familiarity with the bio-pharmaceutical, 
pharmacodynamic and pharmacokinetic activity of a 
substance in the body. 
82 92 83 69 91 80 73 69 92 22 
54 
2. Supply of appropriate medicines taking into account 
dose, correct formulation, concentration, administration 
route and timing. 
100 100 92 92 100 93 96 92 100 8 
55 
3. Critical evaluation of the prescription to ensure that it 
is clinically appropriate and legal. 
95 92 92 92 91 100 96 91 100 9 
56 
4. Familiarity with the supply chain of medicines and the 
ability to ensure timely flow of drug products to the patient. 
76 92 92 75 87 93 83 75 93 18 
57 
5. Ability to manufacture medicinal products that are not 
commercially available.  
81 83 73 33 82 53 34 33 83 50 
 Group 16. Patient care competences: patient education.           
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Table A1. Cont. 
Seq. Competence Belgium 
Czech 
Republic 
Germany Ireland Spain 
The 
Netherlands 
United 
Kingdom 
Min. Max. 
Range: 
max–min. 
58 
1. Promotion of public health in collaboration with other 
actors in the healthcare system. 
77 75 67 77 91 60 91 60 91 31 
59 
2. Provision of appropriate lifestyle advice on smoking, 
obesity, etc. 
59 83 58 85 96 47 93 47 96 49 
60 
3. Provision of appropriate advice on resistance to 
antibiotics and similar public health issues. 
90 83 82 92 100 80 98 80 100 20 
 
Group 17. Patient care competences: provision of 
information and service. 
          
61 
1. Ability to use effective consultations to identify the 
patient's need for information. 
86 92 92 85 91 93 98 85 98 13 
62 
2. Provision of accurate and appropriate information on 
prescription medicines. 
100 92 83 100 91 100 95 83 100 17 
63 
3. Provision of informed support for patients in selection 
and use of non-prescription medicines for minor ailments 
(e.g., cough remedies...) 
90 92 83 100 96 100 93 83 100 17 
 
Group 18. Patient care competences: monitoring of 
drug therapy. 
          
64 
1. Identification and prioritisation of problems in the 
management of medicines in a timely manner and with 
sufficient efficacy to ensure patient safety. 
90 100 91 100 91 100 98 90 100 10 
65 
2. Ability to monitor and report to all concerned in a 
timely manner, and in accordance with current regulatory 
guidelines on Good Pharmacovigilance Practices (GVPs), 
Adverse Drug Events and Reactions (ADEs and ADRs).  
70 82 82 92 100 73 87 70 100 30 
66 
3. Undertaking of a critical evaluation of prescribed 
medicines to confirm that current clinical guidelines are 
appropriately applied.  
71 80 82 85 91 93 82 71 93 22 
Pharmacy 2015, 3        151 
 
Table A1. Cont. 
Seq. Competence Belgium 
Czech 
Republic 
Germany Ireland Spain 
The 
Netherlands 
United 
Kingdom 
Min. Max. 
Range: 
max–min. 
 
Group 19. Patient care competences: evaluation  
of outcomes. 
          
67 
1. Assessment of outcomes on the monitoring of patient 
care and follow-up interventions. 
78 80 60 85 90 73 87 60 90 30 
68 2. Evaluation of cost effectiveness of treatment. 53 80 30 25 67 73 78 25 80 55 
Seq.: sequential numbering (as in Figure 1); Min.: minimum; Max.: maximum; Note that the numbering of the groups of competences starts at 7, i.e., after the 6 questions 
on profile. 
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